Strides gains an FDA approval

BUFFALO GROVE -- Akorn-Strides Friday announced the approval of an ANDA for Rifampin for injection USP, 600 mg/vial. This is the first lyophilized injectable product approval for the joint venture. Akorn-Strides is a Joint Venture that was formed in 2005 by Akorn Inc. and Strides Arcolab Ltd. The primary mission for the joint venture is to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets with a major focus on anti-infectives and analgesics.